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acid metabolism in a rat model of the metabolic
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Ameer Y Taha1†, Fei Gao1†, Epolia Ramadan1, Yewon Cheon1, Stanley I Rapoport1 and Hyung-Wook Kim1,2*Abstract
Background: In animal models, the metabolic syndrome elicits a cerebral response characterized by altered
phospholipid and unesterified fatty acid concentrations and increases in pro-apoptotic inflammatory mediators that
may cause synaptic loss and cognitive impairment. We hypothesized that these changes are associated with
phospholipase (PLA2) enzymes that regulate arachidonic (AA, 20:4n-6) and docosahexaenoic (DHA, 22:6n-6) acid
metabolism, major polyunsaturated fatty acids in brain. Male Wistar rats were fed a control or high-sucrose diet for
8 weeks. Brains were assayed for markers of AA metabolism (calcium-dependent cytosolic cPLA2 IVA and
cyclooxygenases), DHA metabolism (calcium-independent iPLA2 VIA and lipoxygenases), brain-derived neurotrophic
factor (BDNF), and synaptic integrity (drebrin and synaptophysin). Lipid concentrations were measured in brains
subjected to high-energy microwave fixation.
Results: The high-sucrose compared with control diet induced insulin resistance, and increased phosphorylated-
cPLA2 protein, cPLA2 and iPLA2 activity and 12-lipoxygenase mRNA, but decreased BDNF mRNA and protein, and
drebrin mRNA. The concentration of several n-6 fatty acids in ethanolamine glycerophospholipids and
lysophosphatidylcholine was increased, as was unesterified AA concentration. Eicosanoid concentrations
(prostaglandin E2, thromboxane B2 and leukotriene B4) did not change.
Conclusion: These findings show upregulated brain AA and DHA metabolism and reduced BDNF and drebrin, but
no changes in eicosanoids, in an animal model of the metabolic syndrome. These changes might contribute to
altered synaptic plasticity and cognitive impairment in rats and humans with the metabolic syndrome.
Keywords: Arachidonic acid, Docosahexaenoic acid, BDNF, Brain, Polyunsaturated fatty acids (PUFA), Metabolic
syndrome, Drebrin, Sucrose, Insulin resistanceBackground
The metabolic syndrome is a clinical disorder charac-
terized by obesity, hypertension, dyslipidemia, glucose
intolerance and peripheral inflammation [1-3], and is a
risk factor for cognitive decline and mood disorders
[4-8]. In rodent models of the metabolic syndrome,
behavioral abnormalities have been linked to cerebral* Correspondence: peterkhw@gmail.com
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reproduction in any medium, provided the orhypoglycemia [9] and increased cytokine production [10],
and changes in brain lipid metabolism [11,12].
The brain is highly enriched with the polyunsaturated
fatty acids (PUFAs), arachidonic acid (AA, 20:4n-6) and
docosahexaenoic acid (DHA, 22:6n-3) [13-15], which
mostly are esterified in the stereospecifically numbered-2
position of membrane phospholipids. AA and DHA are
essential for mediating neuroreceptor signaling, while
excessive AA is released during neuroinflammation and
excitotoxicity [16-19]. Stimulation of AA signaling by
glutamatergic, serotonergic, cholinergic or dopaminergic
neuroreceptors, among others, triggers AA release byd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(cPLA2 IVA) (reviewed in [19]). Unesterified AA is a
precursor of prostaglandins, thromboxanes, leukotrienes,
and related compounds that have important roles in
regulating the brain’s neuroinflammatory response [13-
15,20-25]. Stimulation of DHA release from membrane
phospholipid via DHA-selective calcium-independent
iPLA2 type VIA is thought to be neuroprotective,
and shows anti-inflammatory effects based on in vitro
and in vivo studies [17,26-30]. Disturbed brain AA and
DHA metabolism has been linked to a number of neurode-
generative diseases, including Alzheimer’s disease and bi-
polar disorder [31-33], which are more common in
individuals with the metabolic syndrome [4-8].
Brain lipid metabolism is altered in the metabolic
syndrome. In a rat model of intracerebroventricular
streptozotocin-induced brain insulin resistance and hypo-
glycemia, cerebral cortex concentrations of ethanola-
mine glycerophospholipid (EtnGpl) and phosphatidylserine
(PtdSer) were decreased, while concentrations of unesteri-
fied palmitate, stearate and AA were increased, suggesting
increased PLA2-mediated membrane degradation [11,12].
Brain phospholipid concentration was reported reduced
in a genetic mouse model of diabetes [34]. An increased
hippocampal malonaldehyde concentration, a marker of
PUFA oxidative degradation, was reported in the hippo-
campus of genetically obese and hypertensive rats [35].
Taken together, these studies suggest an effect of the
metabolic syndrome on the enzymes that regulate brain
PUFA metabolism, such as AA-selective cPLA2 IVA and
iPLA2 VIA, which prefers DHA but also can release AA
[36,37].
Unesterified AA can be converted to pro-inflammatory
and pro-apoptotic secondary mediators, such as prostaglan-
din E2 (PGE2), thromboxane B2 (TXB2) 82 and leukotriene
B4 (LXB4), via cyclooxygenase-2 (COX-2) or 5, 12 and 15
lipoxygenase (LOX) [17,38]. These eicosanoids can cause
synaptic-dendritic injury by reducing brain levels of
trophic factors, such as brain-derived neurotrophic factor
(BDNF) [39,40]. In this regard, studies reported decreased
BDNF and synaptic loss [41-43] in association with cog-
nitive impairment and behavioral changes, in animal
models of the metabolic syndrome [10,41,44]. Although
iPLA2 VIA can regulate peripheral glucose-stimulated
insulin secretion, apoptosis and mitochondrial fatty acid
oxidation [45,46], its involvement in modulating brain
lipid metabolism in the metabolic syndrome is not
known [38].
In view of the reported changes in brain concentrations
of phospholipids and PUFAs, and of neuronal loss in ani-
mal models of the metabolic syndrome [41-43], we
hypothesized correlated disturbances in brain cPLA2
IVA and iPLA2 VIA expression, fatty acid concentra-
tions, synaptic loss, BDNF, and PGE2, TXB2 and LXB4concentrations. Such changes have been reported in
animal models of neuroinflammation [47-49].
To test this hypothesis, we induced early-stage meta-
bolic syndrome by feeding rats a high-sucrose diet for 8
weeks. In this model, feeding a high-sucrose diet induces
time-dependent changes in insulin-resistance and in other
markers of the metabolic syndrome after 8 weeks [50],
without causing diabetic pathology, fatty liver or weight
gain [50-52], which may independently alter brain lipid
metabolism [53]. Insulin resistance can be induced in this
model without changing the fat composition of the diet,
thereby eliminating confounding effects of diet on brain
fatty acid composition [53]. In sucrose and control diet
fed rats maintained for 8 weeks, we examined brain 1)
expression of enzymes involved in AA and DHA metabol-
ism (i.e., mRNA, protein and / or activity of cPLA2, iPLA2
COX-1, COX-2 and 5-, 12- and 15-LOX); 2) concentra-
tions of PGE2, TXB2 and LXB4; 3) mRNA levels of glial-
fibrillary acidic protein (GFAP) and tumor-necrosis
factor-α (TNF-α), because of reported changes in these in-
flammatory markers in animal models of the metabolic
syndrome [10]; 4) expression of BDNF, and of synaptophy-
sin and drebrin as markers of synapto-dendritic injury
[54]; and 5) esterified fatty acid concentrations in
phospholipid subclasses, as well as unesterified fatty
acids and lysophosphatidylcholine (lysoPC), as markers
of phospholipid degradation. These measurements were
performed to test whether phospholipase-mediated phos-
pholipid breakdown occurs in this dietary rat model of the
metabolic syndrome, in association with neuroinflamma-
tion and synapto-dendritic injury. These pathways are
physiologically related because cytokine-induced inflam-
mation, if present in the metabolic syndrome, can alter
the expression AA or DHA-selective PLA2’s and their
downstream metabolites (e.g. eicosanoids) that modu-
late synapto-dendritic integrity and BDNF expression
(reviewed in [55]).
Results
Weight gain and food intake
Figure 1 shows body weight (1-A) and food intake (1-B)
over the 8-week course of the study. Two-way repeated
measures analysis of variance revealed a significant main
effect of time on weight and food intake, both of which
increased. No significant effect of diet or interaction be-
tween diet and time was seen. Consistent with the lack of
difference in body weight, weights of brain, liver, adipose
tissue, heart, kidneys and testes, collected at the time of
sacrifice, did not differ significantly between the two
groups (data not shown, p > 0.05 by unpaired t-test).
Oral glucose tolerance test
Rats fed the high-sucrose diet showed evidence of
impaired glucose metabolism, measured by an oral glucose
A. Body weight over time in rats fed a control or high-sucrose diet
B. Food intake over time in rats fed a control or high-sucrose diet
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Figure 1 (A) Body weight and (B) food intake over time in rats fed a control or high- sucrose diet. Data are means ± SD (n = 6). Two-way
repeated measures analysis of variance revealed a significant effect of time only on body weight gain and food intake.
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measures analysis of variance showed a significant main
effect of diet and time on whole blood glucose concen-
trations at 4 (Figure 2A) and 8 weeks (Figure 2B). At
4 and 8 weeks, fasting whole blood glucose concentra-
tion was similar between the two groups at baseline.
The glucose concentration was increased after an oral
preload of glucose (5 g/kg) and remained higher than
baseline values by the end of the 2 h test. The rise in
blood glucose concentration was significantly higher for
the high-sucrose compared to control rats, suggesting
reduced glucose tolerance in the sucrose- group.ß-hydroxybutyrate in whole blood
Fasting ß-hydroxybutyrate concentration in whole blood, a
marker of ketosis, was measured at 4 and 8 weeks, before
starting the oral glucose tolerance test (Table 1). There was
a significant effect of time on fasting ß-hydroxybutyrate
concentration, but no effect of treatment or an interactionbetween time and diet. ß-hydroxybutyrate concentrations
were significantly reduced for both dietary groups at 8
weeks compared to 4 weeks (p< 0.05).Plasma insulin, glucose and triglyceride concentrations
Rats on the high-sucrose diet showed insulin resistance
and hypertriglyceridemia at 8 but not 4 weeks (Table 1).
There was a significant interaction between time and
diet (p < 0.05) for fasting plasma, insulin, and triglyceride
concentrations, and the homeostasis model assessment
(HOMA) insulin-resistance index, calculated as previ-
ously described [56]. There was a significant main effect
of diet on plasma glucose and triglyceride concentra-
tions, and on the HOMA index. Time was a significant
factor affecting glucose, insulin and triglyceride concen-
trations, and the HOMA index. Compared to controls,
rats fed the high-sucrose diet had significantly higher
plasma concentrations of glucose and triglycerides and
HOMA index at 8 weeks.
(A) 
(B) 
Figure 2 Oral glucose tolerance test in rats fed a control or
high-sucrose diet. Blood glucose concentrations were measured by
a glucometer after a 10 h fast at 0 and 15, 30, 34, 60, 90 and 120
min following gavage with 5g/kg of an oral glucose preload at (A) 4
weeks and (B) 8 weeks of treatment. Two-way repeated measures
analysis of variance showed a significant main effect of diet and
time on blood glucose concentrations at 4 and 8 weeks.
Table 1 Plasma glucose, insulin and triglyceride concentratio
ß-hydroxybutyrate concentrations at 4 and 8 weeks of feedin
4 weeks 8 w
Parameter Control High-sucrose Co
Glucose (mmol/L) 4.0 ± 0.41 4.4 ± 0.1 4.1
Insulin (ng/ml) 0.6 ± 0.4 0.3 ± 0.1 0.7
HOMA1 index 2.3 ±1.91 1.4 ± 0.41 4.1
Triglycerides (mg/ml) 0.9 ± 0.2 0.7 ± 0.2 0.7
β-hydroxybutyrate (mmol/L) 0.9 ± 0.2 0.9 ± 0.2 0.6
Values are means ± SD (n = 8) 1n=7 due to insufficient sample. 1n=7 due to insuffic
followed by a one-way ANOVA and Bonferroni’s post-hoc test comparing high-sucro
significant difference compared to 8-week control mean.
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mRNA and protein levels of brain cPLA2 IVA did not
differ significantly between rats fed the high sucrose and
the control diet for 8 weeks (Figure 3A and 3B). The
protein level of phosphorylated-cPLA2 (phospho-
cPLA2), which represents the active form of cPLA2
[57,58], was increased significantly in the high-sucrose
group compared to the control group (Figure 3C). Con-
sistent with the increase, in phosphorylated-cPLA2 activity
of cPLA2 was significantly increased in the high-sucrose
group (Figure 3D).
iPLA2 and sPLA2 mRNA, protein and activity
iPLA2 VIA and sPLA2 IIA mRNA and protein did not
differ significantly between rats fed the high sucrose and
the control diet for 8 weeks (Figure 4A, B, D, E). The ac-
tivity of iPLA2 was significantly increased in the high-
sucrose group (Figure 4C), whereas sPLA2 activity did
not differ significantly between the groups (Figure 4F).
PGE2, TXB2 and LTB4 concentrations
There was no significant difference in PGE2, LTB4 or TXB2
concentration between the two groups (Figure 5A-C).
GFAP, TNF-α, COX and LOX mRNA
There was no significant change in GFAP or TNF-α
mRNA (data not shown). mRNA levels of COX-1 and
COX-2 also were not affected by the high-sucrose diet
(data not shown), nor was 5- or 15-LOX mRNA chan-
ged significantly. Brain 12-LOX mRNA was increased
significantly (control, 1.00 ± 0.07; high-sucrose, 1.22 ±
0.05; p < 0.05 by unpaired t-test).
mRNA and protein levels of BDNF and synaptic markers
Compared with control diet, the high-sucrose diet
decreased significantly mean protein and mRNA levels
of BDNF (Figure 6A and B). mRNA and protein levels of
the pre-synaptic marker synaptophysin did not differ sig-
nificantly between the groups (Figure 6C and D). There
was a significant decrease in mRNA of the post-synapticns, calculated HOMA index and whole blood
g control or high-sucrose diet
eeks
ntrol High-sucrose Time Diet Time x Diet
± 1.0 6.0 ± 1.8*** <0.05 <0.01
± 0.3 1.8 ± 0.9** <0.001 <0.05
± 4.1 10.5 ± 4.8** <0.001 <0.05 <0.05
± 0.3 1.5 ± 0.5** <0.05 <0.05 <0.01
± 0.2 0.7 ± 0.11 <0.05
ient sample. Data were analyzed by two-way repeated measures ANOVA,
se versus controls at 4 and 8 weeks. **p < 0.01; ***p < 0.001 indicates
Figure 3 mRNA, protein and activity of cPLA2 and phosphorylated (phospho)-cPLA2 protein in brain of rats fed the control or high-
sucrose diet for 8 weeks. A) cPLA2 (IVA) mRNA, B) cPLA2 (IVA) protein, C) phospho- cPLA2 (IVA) protein and D) cPLA2 activity. Data are
expressed as the relative level of the cPLA2 normalized to the endogenous control (β-globulin) using the ΔΔCT method. Protein level is the ratio
of optical density of cPLA2 to β–actin, expressed as percent of control. Values are mean ± SD (n = 8 for both groups). *p < 0.05, **p < 0.01 by
unpaired t-test.
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significant change in its protein level (Figure 6F).Brain fatty acid concentrations
There were few significant differences in brain esterified
fatty concentrations (data not shown): a 12-16% increase
in AA (6262 ± 459 nmol/g brain wet wt, control, 7234 ±
468 nmol/g wet wt, sucrose) and adrenate (22:4n-6;
3321 ± 275 nmol/g wet wt, control, 3738 ± 158 nmol/g
wet wt, sucrose) in EtnGpl, and a 29% increase in
dihomo-γ-linolenic acid (20:3n-6; 7 ± 1 nmol/g wt wet,
control, 9 ± 1 nmol/g wt wet, sucrose) in lysoPC in rats
on the high-sucrose compared to control diet (p < 0.05).
For unesterified fatty acids, one sample from the high-
sucrose group was excluded from the analysis because
its unesterified AA concentration was 3-fold higher than
the mean, which suggests ischemia caused by incomplete
microwave-fixation [59]. The unesterified AA concentra-
tion was significantly increased (by 20%) in the high-
sucrose diet group, whereas the DHA concentration did
not differ significantly from control (Figure 7). Other
unesterified fatty acid concentrations also did not differ
between the groups (data not shown).Discussion
Rats fed the high-sucrose diet (60% sucrose) for 8 weeks
did not show obesity or increased food intake, but devel-
oped hypertriglyceridemia and insulin resistance, two
components of the metabolic syndrome, as reported
[50-52]. At 8 weeks, some brain enzymatic markers of
AA and DHA metabolism were increased significantly
in the high sucrose compared with control diet group
(e.g., protein level of phospho-cPLA2, activities of cPLA2
and iPLA2) as was the esterified AA concentration in
EtnGpl and unesterified AA concentration. BDNF mRNA
and protein and drebrin mRNA were reduced, but synap-
tophysin mRNA and protein were not altered. Feeding
the high-sucrose diet for 8 weeks did not change PGE2,
TXB2 or LTB4 concentration significantly. Because the
8-week high-sucrose feeding paradigm represents early-
stage metabolic syndrome in the absence of pathological
diabetes or obesity [50,51], these findings demonstrate
changes in brain PUFA metabolizing enzymes and com-
position in association with reduced BDNF and drebrin
mRNA at an early disease stage.
The upregulation of brain cPLA2 and iPLA2 enzyme
activities (Figure 3 and 4) in the high-sucrose fed rats
suggests an increase in brain AA and DHA metabolism.
Figure 4 mRNA, protein and activity of brain iPLA2 and sPLA2 in rats fed the control or high-sucrose diet for 8 weeks. iPLA2 (VIA) A)
mRNA, B) protein and C) activity; sPLA2 (IIA) E) mRNA, F) protein and G) activity. Data are expressed as the relative level of the iPLA2 and sPLA2
normalized to the endogenous control (β-globulin) using the ΔΔCT method. Protein level is the ratio of optical density of iPLA2 and sPLA2 to
β–actin, expressed as percent of control. Values are mean ± SD (n = 8 for both groups). ***p < 0.001 by unpaired t-test.
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olism has been reported in humans and rats with the
metabolic syndrome [60,61]. A positron emission tomog-
raphy study demonstrated increased brain uptake of [11C]
palmitate and [18F]fluoro-6-thia-heptadecanoic acid in
patients with the metabolic syndrome [60]. Hypothalamic
concentrations of long-chain saturated acyl-CoAs wereFigure 5 Levels of A) PGE2, B) LTB4, and C) TXB2 in brain of rats fed a
were extracted according to the method of Radin [82] and analyzed using
mean ± SD (n = 8 for both groups). *p < 0.05 by unpaired t-test.increased in a high-fat diet animal model of the metabolic
syndrome, also indicating increased metabolism of long-
chain saturated fatty acids [61]. Taken together, the results
suggest non-specific upregulation in brain fatty acid me-
tabolism, including PUFAs, associated with the meta-
bolic syndrome. Upregulated AA or DHA metabolism
could be directly confirmed in this animal model, usingcontrol or high-sucrose diet for 8 weeks. PGE2, LTB4, and TXB2
a polyclonal enzyme-linked immunosorbent assay. Values are
Figure 6 mRNA and protein levels of BDNF and synaptic markers in brain of rats fed a control or high-sucrose diet for 8 weeks. A)
BDNF mRNA, B) BDNF protein, C) synaptophysin mRNA, D) synaptophysin protein, E) drebrin mRNA and F) drebrin protein. Data are expressed as
relative level of BDNF, synaptophysin and drebrin normalized to endogenous control (β-globulin) using the ΔΔCT method. The BDNF protein
level was measured by an ELISA kit. The protein level is the ratio of optical density of synaptophysin or drebrin to β–actin, expressed as percent
of control. Values are mean ± SD (n = 8 for both groups). *p < 0.05 by unpaired t-test.
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following radiotracer injection, or can be examined in
humans using positron emission tomography [31,38,62].
The released fatty acids may be alternative energy sub-
strates to glucose for brain metabolism, due to cerebral
hypoglycemia caused by insulin-resistance. This is con-
sistent with evidence of increased brain activity of carni-
tine palmitoyltransferase (which regulates fatty acid
entry from the acyl-CoA pool into mitochondria for later
β-oxidation) in an animal model of the metabolic syn-
drome [34]. 14C-palmitate conversion to 14C-CO2 alsowas increased in mitochondrial brain extracts of diabetic
(db/db) mice [34].
Brain cPLA2 activity and phospho-cPLA2 protein, a
marker of activated cPLA2 [57,58], were increased in the
high-sucrose fed rats in the absence of changes in cPLA2
mRNA or protein, suggesting post-translational modifi-
cation and upregulated brain AA metabolism, consist-
ent with the increased unesterified AA concentration
(Figure 7). Increased activation of cPLA2 may reflect
excitotoxicity associated with increased influx of extra-
cellular calcium into the cell via ionotropic glutamatergic
Figure 7 Brain concentrations of unesterified AA and DHA in
rats fed a control or high-sucrose diet for 8 weeks. Values are
mean ± SD (n = 8 for both groups). *p < 0.05 by unpaired t-test.
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via G-proteins to dopaminergic, serotonergic and mus-
carinic neuroreceptors [19], an increase in its activity
suggests disturbed G-protein neuroreceptor signaling in
the metabolic syndrome [64]. Cytokine receptor activa-
tion may also initiate cPLA2 activation [65], although our
findings do not suggest an increase in cytokine expres-
sion in rats fed the high-sucrose diet.
iPLA2 is insensitive to extracellular calcium influx into
the neuron [24,63], but can be activated by intracellular
calcium (at mM concentrations) released from the endo-
plasmic reticulum by the calcium-releasing ryanodine
receptor [66]. Mobilization of intracellular calcium
stores can be mediated by increased intracellular unes-
terified AA levels, which was reported to activate the
ryanodine receptor in vitro [66]. This is in agreement
with the finding that the unesterified AA concentration
was increased in the high-sucrose diet rats (Figure 7).
Likely, this increase in AA concentration occurred intra-
cellularly, since sPLA2, which releases AA extracellularly,
was not changed significantly (Figure 4).
Concentrations of pro-inflammatory eicosanoids (PGE2,
TXB2 and LTB4) did not differ between the groups
(Figure 5). It is possible, however, that changes in eico-
sanoids or cytokines [65] occurred in specific brain
regions such as the hippocampus, as reported in gen-
etically diabetic mice, or that longer administration of
the high-sucrose diet sufficient to initiate diabetes would
increase whole brain cytokine levels [10]. However,
consistent with the lack of significant changes in the
three eicosanoids, we did not find significant changes
in mRNA levels for COX-1, COX-2, 5- or 15-LOX in the
high-sucrose fed rats, nor in TNF-α or GFAP mRNA,
suggesting the absence of neuroinflammation, since
transcription of these molecular markers occurs within
transcriptional circuits related to neuroinflammation
[67-69].
Whole brain BDNF mRNA and protein levels were
reduced in the high-sucrose group (Figure 6), inagreement with previous studies that showed reduced
BDNF levels in animal models of the metabolic syn-
drome with behavioral impairment [10,41,42]. Reduced
BDNF expression was not mediated by pro-inflammatory
eicosanoids, which were not changed. One possibility is
that the increased unesterified AA concentration in the
high-sucrose animals decreased BDNF and induced
apoptosis, as reported in cultured spinal cord neurons
[70]. Reduced BDNF expression in the sucrose-fed rats
may have promoted dendritic injury, which was indirectly
suggested by the reduction in drebrin mRNA (Figure 6),
or have altered the cellular dynamics and structural
organization of dendritic spines in the absence of
changes in drebrin protein. Changes in dendritic
morphology and dynamics could be the topic of future
studies. Additionally, more severe changes in synaptic
structure are likely to occur with prolonged exposure to
the high-sucrose diet, since the 8-week feeding paradigm
causes only early-stage metabolic syndrome without
obesity, diabetes or liver damage [41,44,52].
Contrary to reports using other models involving cen-
tral insulin resistance [12,34,42], we did not find evidence
of phospholipid degradation in the brain, since phospho-
lipid mass, derived by the summation of total fatty acids
within each phospholipid class, did not differ between
the dietary groups (Table 1). Also, lysoPC, a marker of
phospholipid breakdown, was not changed (Table 1). The
changes in phospholipid fatty acid concentrations were
relatively minor, and were significant only for a few n-6
PUFAs in EtnGpl (AA and 22:4n-6) and in lysoPC
(20:3n-6).
Conclusion
In summary, brain enzymatic markers of AA and DHA
metabolism were increased in a rat model of early-stage
metabolic syndrome, in association with reduced BDNF
mRNA and protein, and drebrin mRNA. Increases in
cPLA2 and iPLA2 activities support the notion of
phospholipase-mediated neurodegeneration [11,12,34,35].
The decreases in BDNF and drebrin suggest increased
susceptibility to synapto-dendritic injury.
In the future, an upregulation in brain AA and DHA
metabolism associated with the metabolic syndrome
might be imaged in humans with positron-emitting
tomography using radiolabeled AA or DHA [31,62], as
biomarkers of disease progression [4,5,71]. Therapeutic
strategies aimed at downregulating brain PUFA metabol-
ism, such as the administration of carnitine palmitoyl-
transferase inhibitors [72,73] or PLA2 inhibitors (e.g. the
mood stabilizers, lithium and carbamazepine), might be
effective in slowing the progression of brain lipid abnor-
malities identified in this study, the associated changes in
synaptic loss and possibly, cognitive dysfunction in the
metabolic syndrome.
Table 2 Composition of control diet and high-sucrose
diet







Maltose Dextrin 150 0
Hydrogenated coconut oil 60 60
Safflower oil 32.3 32.3





Choline bitartrate 2.5 2.5
t-Butylhydroquinone 0.02 0.02
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Animals
The protocol was approved by the Animal Care and Use
Committee of the Eunice Kennedy Schriver National
Institute of Child Health and Human Development
and followed the National Institutes of Health Guide for
the Care and Use of Laboratory Animals (NIH Publica-
tion No. 80–23). Post-weaning male Wistar rats pur-
chased from Charles River Laboratories (Portage, MI,
USA) were housed in an animal facility with regulated
temperature, humidity, and a 12 h light/12 h dark cycle.
After weaning, pups were divided randomly into control
diet (n = 14) and high sucrose diet (n = 14) groups. The
metabolic syndrome was confirmed in 8 out of 14 rats
per dietary group, by measuring body weight and food
intake weekly, and measuring tail vein plasma glucose,
insulin and triglyceride concentrations at 4 and 8 weeks.
An oral glucose tolerance test was also administered at
4 and 8 weeks to the same rats (n = 8 rats per group) as
described below. After 8 weeks on a chosen diet, half the
rats from each dietary group (n = 8 per group) were
asphyxiated by CO2 inhalation, decapitated and their
brains excised rapidly, frozen in 2-methylbutane with
dry ice at −50°C, and stored at −80°C until use. Brain,
testes, adipose tissue, liver and heart were collected,
weighed, frozen in 2-methylbutane and stored at −80°C.
Brain lipids and eicosanoids (PGE2, TXB2 and LTB4)
were measured in the remaining animals (n = 6 per roup)
that had undergone a catheter implantation surgery
followed by a 2-h infusion protocol of [D5]-α-linolenic
acid (17, 17, 18, 18, 18-D5) and [U-13C]-linoleic acid
(Spectra Stable Isotopes, Columbia, MD, USA) to assess
liver PUFA kinetics (Taha et al., unpublished). After the
2 h infusion, the rats were lightly anesthetized with
sodium pentobarbital (50 mg/kg; Abbott Laboratories,
Chicago, IL, USA) and subjected to head-focused micro-
wave irradiation stop brain lipid metabolism (5.5 kW,
4.8 s; Cober Electronics, Stamford, CT, USA) [74]. Brains
were excised, separated sagittally into two halves and
stored at −80°C until analyzed.
Diets
The control and high sucrose diets were obtained from
Dyets Inc. (Bethlehem, PA, USA), and were based on the
AIN-93G formulation [75]. The diets were isocaloric
and identical in macronutrient and micronutrient com-
position, but differed in carbohydrate composition. The
control diet contained cornstarch (150 g/kg diet),
sucrose (100 g/kg), dextrose (200 g/Kg) and maltose dex-
trin (150 g/kg). The high-sucrose diet contained sucrose
(600 g/kg) as the sole carbohydrate source (Table 2). The
fatty acid composition of the diets was identical, and
contained 7.8 μmol/g α-LNA (4.6% total fatty acid),
which is the minimum level of α-LNA for n−3 PUFAadequacy in rodents, 40 μmol/g LA (25% total fatty
acid), 110 μmol/g saturated fatty acid (68.5% of total),
and 10 μmol/g monounsaturated fatty acid [76]. Other
PUFAs, including AA and DHA were absent.Plasma glucose, insulin, and triglyceride measurement
Blood was collected at 4 and 8 weeks from the tail vein
after an overnight 10 h fast (n = 8 per group), and plasma
glucose, insulin and triglyceride concentrations were
determined with a glucose oxidase kit (Sigma), an Insulin
ELISA kit (Alpco Diagnostics, Salem, NH, USA) and a
triglyceride kit (Sigma), respectively. The insulin and
glucose concentrations were used to calculate the
‘homeostasis model assessment’ (HOMA) index of in-
sulin resistance, by multiplying glucose (mmol/L) and in-
sulin (mU/L) concentrations, and dividing by 22.5 [56].Oral glucose tolerance test and β-hydroxybutyrate
measurement
An oral glucose tolerance test [77,78] was performed
at 4 and 8 weeks post-weaning, 2 days after the tail
vein blood withdrawals described above. For this test,
blood was obtained by tail-prick using a sharp needle.
After an overnight 10 h fast, baseline blood glucose
and ß-hydroxybutyrate concentrations were assayed
using a commercial glucometer (LifeScan, Milpitas,
CA, USA). The rats then were gavaged with 0.375 g
glucose/ml (5 g glucose/kg body wt), and blood glu-
cose concentrations were determined 15, 30, 45, 60,
90, and 120 min later.
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Brain total lipids were extracted by the Folch method
[79]. An aliquot of the total lipid extract was methylated
with 1% H2SO4-methanol for 3 h at 70°C, or separated
into phospholipid subfractions with thin layer chroma-
tography (TLC) using heptane / diethyl ether / acetic acid
(60:40:3 v/v/v) as a solvent. Unesterified fatty acids were
separated with TLC using chloroform / methanol / acetic
acid / water (60:50:1:4 v/v/v/v). Prior to methylation,
di-17:0 PC was added as an internal standard to total
lipids and phospholipid subfractions. Unesterified 17:0
was added as an internal standard to unesterified fatty
acids. Samples were methylated with 1% H2SO4-methanol
for 3 h at 70°C. The resulting fatty acid methyl esters
were extracted and analyzed using a gas chromatograph
(6890N, Agilent Technologies, Palo Alto, CA, USA)
equipped with an SP-2330 fused silica capillary column
(30 m×0.25 mm i.d., 0.25 μm film thickness) (Supelco,
Bellefonte, PA, USA) and a flame ionization detector.
Concentrations were calculated by proportional compari-
son of peak areas to the area of the 17:0 internal
standard.
Preparation of cytoplasmic and membrane extracts
Cytoplasmic and membrane extracts for Western blots
were prepared using a compartmental protein extraction
kit according to the manufacturer’s instructions (Millipore,
Temecula, CA, USA). Protein concentrations of cyto-
plasmic and membrane extracts were determined using
Bio-Rad Protein Reagent (Bio-Rad, Hercules, CA, USA).
Western Blot Analysis
Proteins from cytoplasmic (50 μg) and membrane extracts
(50 μg) were separated on 4-20% SDS-polyacrylamide
gels (PAGE) (Bio-Rad). Following SDS-PAGE, the pro-
teins were electrophoretically transferred to a nitrocellu-
lose membrane. Protein blots were incubated overnight
at 4°C in Tris-buffered saline (TBS) buffer, containing 5%
nonfat dried milk and 0.1% Tween-20, with specific pri-
mary antibodies (1:1000 dilution) for the group IVA
cPLA2, phospho-cPLA2, group IIA secretory sPLA2,
group VIA iPLA2 (Santa Cruz Biotech, Santa Cruz, CA),
drebrin, synaptophysin (Cell Signaling, Beverly, MA), and
β-actin (Sigma-Aldrich, St. Louis, MO). Protein blots
were incubated with appropriate HRP-conjugated sec-
ondary antibodies (Cell Signaling) and visualized using a
chemiluminescence reaction (Amersham, Piscataway, NJ)
on X-ray film (XAR-5, Kodak, Rochester, NY). Optical
densities of immunoblot bands were measured using
Alpha Innotech Software (Alpha Innotech, San Leandro,
CA) and were normalized to β-actin to correct for un-
equal loading. All experiments were carried out three
times with 8 independent samples per group. Values are
expressed as percent of control.BDNF protein levels
BDNF protein levels were measured in brain cytosolic
extracts using an ELISA kit. according to the manufac-
turer’s instructions (Millipore, Temecula, CA). Values
are expressed in pmol/mg protein.
Total RNA isolation and real time RT-PCR
Total RNA was prepared from brain using commercial
kits (RNeasy Lipid Tissue Kit; Qiagen, Valencia, CA).
cDNA was prepared from total RNA using a high-
capacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA). mRNA levels were measured by real time quan-
titative RT-PCR, using the ABI PRISM 7000 sequence de-
tection system (Applied Biosystems). For specific primers
and probes for target genes, TaqManR gene expression
assays, purchased from Applied Biosystems, consisted of
a 20X mix of unlabeled PCR primers and Taqman minor
groove binder probe (FAM dye-labeled). The fold change
in gene expression was determined using the ΔΔCT
method [80]. Data are expressed as the relative level of
the target gene in the high-sucrose animals normalized
to the endogenous control (β-globulin) and relative to
the control rats (calibrator). All experiments were carried
out in duplicates with 8 independent samples per group.
Phospholipase A2 activities
Sample preparation
Brain tissue was homogenized with 3 vol of homo-
genization buffer (10 mM HEPES, pH 7.5, containing
1 mM EDTA, 0.34 μM sucrose and protease inhibi-
tor cocktail (Roche, Indianapolis, IN)), using a glass
homogenizer. The homogenized sample was centrifuged
at 100,000 g for 1 h at 4°C, and the supernatant was
used for all PLA2 enzyme activity analyses. Supernatants
were kept at −80°C until use. The protein concentration
was analyzed by the Bradford assay (Bio-Rad) [81].
Enzyme assay with radioisotope method
The final incubation volume was 0.5 ml. To measure
cPLA2 activity, the cytosolic fraction (0.3 mg protein
in one assay, ~50 μl) was mixed with 100 mM
HEPES, pH 7.5 containing 80 μM Ca2+, 2 mM dithio-
threitol and 0.1 mg/ml fatty acid-free bovine serum
albumin (total volume = 450 μl). The enzyme reaction
was started by adding fifty μl of substrate solution
containing 100 μM 1-palmitoyl-2-arachidonoyl-sn-glycerol-
3-phosphorylcholine and phosphatidylinositol 4,5-bispho-
sphate (97:3) (Avanti Polar Lipids, Alabaster, AL, USA), and
approximately 100,000 dpm of 1-palmitoyl-2-[1-14C] ara-
chidonoyl-sn-glycerol-3-phosphorylcholine (specific ac-
tivity of 60 mCi/mmol, PerkinElmer, Boston, MA) in 400
μM triton X-100 per assay, To measure iPLA2 activity,
the cytosolic fraction (0.3 mg protein in one assay)
was mixed with 100 mM HEPES, pH 7.5, 5 mM
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volume = 450 μl). Fifty μl substrate mixture of 100 μM
1-palmitoyl-2-palmitoyl-sn-glycerol-3-phosphorylcholine
containing approximately 100,000 dpm of 1-palmitoyl-2-
[1-14C] palmitoyl-sn-glycerol-3-phosphorylcholine (specific
activity of 53 mCi/mmol, Buckinghamshire, UK) in
400 μM Triton X-100 was added to start the enzyme
reaction.
Substrate preparation for radioisotope method
Substrates for the iPLA2 and cPLA2 activity analyses
described above were prepared daily. Appropriate amounts
of cold and radiolabeled phospholipids were added to an
appropriate amount of Triton X-100, and the mixture
was dried with nitrogen gas. Water was added to the resi-
dues to give a 10x lipid mixture (1 mM phospholipid,
1,000,000 dpm, and 4 mM Triton X-100), which was
mixed vigorously.
Enzyme assay
The cytosolic fraction (0.3 mg in one assay) was mixed
with the assay mixture (total volume of 450 μl), and 50 μl
substrate mixture was added to start the enzyme reac-
tion. The reaction mixture was incubated for 30 min at
40°C, and then 2.5 ml of Dole reagent (2-propanol,
heptane: 0.5M H2SO4, 400:100:20, vol/vol/vol) was added
to stop the reaction. One and a half ml of heptane and
1.5 ml H2O were added to the mixture, followed by
vortexing and centrifugation at 3000 rpm for 5 minutes.
The upper phase (about 2 ml) was transferred to a tube
containing 200 mg of silicic acid (200–400 mesh), fol-
lowed by vortexing and centrifugation. The supernatant
(1.5 ml) was transferred to a scintillation vial, and scintil-
lation cocktail was added (Ready Safe™ plus 1% glacial
acetic acid). Radioactivity of the released unesterified
fatty acid from the phospholipid substrate was counted
on a liquid scintillation counter (2200CA, TRI-CARBW,
Packard Instruments, Meriden, CT, USA). iPLA2 and
cPLA2 activities were expressed as the release rate of
fatty acid from phospholipids.
sPLA2 activity
sPLA2 activity was measured using an appropriate assay
kit (Cayman, Ann Arbor, MI, USA), according to the
manufacturer’s instructions.
PGE2, TXB2, and LTB4 concentration
PGE2, TXB2, and LTB4 were extracted according to the
method of Radin [82]. A portion of the extract was dried
under nitrogen and assayed for PGE2, TXB2, and LTB4
using a polyclonal enzyme-linked immunosorbent assay
according to the manufacturer’s instructions (Oxford
Biomedical Research, Oxford, MI).Data and statistics
Data are presented as means ± SD (n = 8 for each
group). A two-way repeated measured analysis of vari-
ance (ANOVA) was used to test for effects of time and
treatment on body weight, food intake, and insulin,
glucose, β-hydroxybutyrate and triglyceride concentra-
tions, and the response to an oral glucose preload per-
formed at 4 and 8 weeks. An unpaired Student’s t-test
was used to compare means, taking p < 0.05 as the cut
off for statistical significance.
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